fbpx Skip to main content


Iqbal Grewal, Ph.D., D.Sc., F.R.C.Path

Iqbal Grewel

Iqbal Grewal, Ph.D., D.Sc., F.R.C.Path is Vice President, Head of Immuno-Oncology in the Oncology Therapeutic Area at Janssen Research & Development, LLC.  He leads research efforts at Janssen to discover and develop therapeutics that function as immune modulators for the treatment of cancer. He is responsible for formulating and executing immuno-oncology strategy across all areas of disease focus.

Prior to Janssen, Iqbal led research and development activities at ImmunGene Inc., as Chief Scientific Officer and was a member of the Board of Directors. At ImmunGene, his strong scientific leadership helped to build a diverse portfolio of antibody-cytokine fusion proteins as candidates to treat cancers.

Iqbal joined ImmunGene from Seattle Genetics, Inc., where he was Vice President, Preclinical Therapeutics. At Seattle Genetics, he managed preclinical translational research functions for development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology. Under his leadership, multiple agents successfully moved to clinical development.

Iqbal began his career in the pharmaceutical industry in 1998 at Genentech Inc., where he pursued research for discovering and developing innovative protein-based biotherapeutics. He identified and validated several novel molecules as therapeutic candidates and translated some of his findings into key drug candidates for clinical development.

Iqbal holds a Doctorate in Immunology from UCLA.  He was awarded a Doctor of Science degree by the University of Aberdeen in Aberdeen, United Kingdom, for his more than 20 years of seminal contributions in research, and has been named a Fellow by the Royal College of Pathologists in London. Iqbal completed his post-doctoral fellowship at Howard Hughes Medical Institute, Yale University School of Medicine, where he continued as a research faculty member.